Koi Vaccine Update23 Dec 2008 07:36
Koi Vaccine Update
The Board of Henderson Morley announces that further to the Chairman's statement which
accompanied the results for the full year, the
initial phase of the field studies has now been completed.
The vaccine candidates under examination were formulated to give a wide range of doses,
using proprietary adjuvants (compounds that help
boost and increase the duration of immune responses). The results from the study have
demonstrated that the vaccine candidates were safe and
well tolerated, with adverse effects no greater than unvaccinated controls.
Fish were vaccinated and examined, amongst other parameters, for immune responses to
vaccination, vaccination dose, vaccination safety
and assessment of the safety and immunogenicity of the new adjuvant. The studies have given a
much greater understanding of immune responses
and dose requirements. It is likely that from the next phase of studies, due to start in Jan
2009, a final vaccine candidate will be
selected.
Commenting on the announcement, Andrew Knight, Henderson Morley Executive Chairman said:
"This is an important first stage in studying
the efficacy of the KHV vaccine. We can now move forwards to the next phase of the study which
we anticipate will start in early January
2009."